secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001193125-26-053009
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome settles SUNOSI patent litigation; generic entry delayed to 2040
----------------------------------------------------------------------

- Alkem can sell generic SUNOSI on/after March 1, 2040 (no pediatric exclusivity) or September 1, 2040 (if granted), subject to FDA approval.
- Settlement resolves Alkem's ANDA patent litigation in District of New Jersey; similar litigation with another party remains pending.
- Agreement submitted to FTC and DOJ for review as required by law.
- No financial terms disclosed in the settlement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526053009/0001193125-26-053009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526053009/axsm-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-053009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer